Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 500-537-5 | CAS number: 161075-00-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: inhalation
Administrative data
- Endpoint:
- sub-chronic toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 19 July 2001 to 01 October 2002
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Remarks:
- OECD Guideline-conform study conducted under GLP.
Cross-reference
- Reason / purpose for cross-reference:
- reference to same study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 001
- Report date:
- 2002
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 413 (Subchronic Inhalation Toxicity: 90-Day Study)
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- Ethene, tetrafluoro-, oxidized, polymd., reduced, decarboxylated
- IUPAC Name:
- Ethene, tetrafluoro-, oxidized, polymd., reduced, decarboxylated
- Reference substance name:
- Tetrafluoroethylene, oxidized, oligomers, reduced, decarboxylated
- EC Number:
- 500-539-6
- EC Name:
- Tetrafluoroethylene, oxidized, oligomers, reduced, decarboxylated
- Cas Number:
- 161075-02-1
- Molecular formula:
- CF2H-O-(CF2-CF2-O)m-(CF2-O)n-CF2H
- Test material form:
- liquid
- Details on test material:
- - Name of test material (as cited in study report): HFPE, H-Galden 8004X
- Molecular formula (if other than submission substance): HCF2O(C2F4O)m(CF2O)nCF2H
- Molecular weight (if other than submission substance): 230-350
- Smiles notation (if other than submission substance): not applicable
- InChl (if other than submission substance): not applicable
- Structural formula attached as image file (if other than submission substance): see Illustration
- Substance type: Pure substance
- Physical state: Liquid
- Analytical purity: >99%
- Impurities (identity and concentrations): not reported
- Composition of test material, percentage of components: (n=0 m=0): 0,3%, (n=1 m=0): 5,6%, (n=0 m=1): 43%, (n=2 m=0): 2,7 %, (n=1 m=1): 18 %, (n=0 m=2): 25%, (n=2 m=1): 5%, (n=1 m=2): 0,2%, (n=0 m=3): 0,1%, (n=2 m=2): 0,1%
- Isomers composition: not reported
- Purity test date: not reported
- Lot/batch No.: 04/01
- Expiration date of the lot/batch: April 2005
- Stability under test conditions: Stable
- Storage condition of test material: Ambient temperature in the dark
Constituent 1
Constituent 2
Test animals
- Species:
- rat
- Strain:
- Crj: CD(SD)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: livestock farming
- Age at study initiation: approximately 8 weeks
- Weight at study initiation: males: 266-324 g, females: 185-245 g
- Fasting period before study: no. Animals had no access to food and water during the 6-hour exposure period and overnight prior to sampling for laboratory investigations.
- Housing: 5 animals/sex/cage
- Diet (e.g. ad libitum): pellet diet ad libitum
- Water (e.g. ad libitum): tap water ad libitum
- Acclimation period: approximately 2 weeks, between arrival of animals and the commencement of exposure.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19-22 (measured)
- Humidity (%): 46-75 (measured)
- Air changes (per hr): not reported
- Photoperiod (hrs dark / hrs light): 12 hour cicle (6 a.m.-6 p.m.)
Administration / exposure
- Route of administration:
- inhalation: vapour
- Type of inhalation exposure:
- whole body
- Vehicle:
- air
- Details on inhalation exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Exposure apparatus: Whole body exposure chambers
- Method of holding animals in test chamber: Animals were placed into individual compartment of the exposure chamber. A separate exposure chamber was used for each group.
- Method of conditioning air: Air supplied to the vapour generators and secondary dilution vessels was filtered to remove any residual particulate and was dried.
- System of generating vapour: The chamber atmospheres were produced by metering the liquid test substance into glass vapour generators through which dried and heated air was passed at a group dependent flow rate ranging from 90 to 150 l/minute and subsequently 60 to 100 l/minute from exposure 40. The flow rate was decrease to conserve test material. For all exposed groups, the vapour/air mixture produced in the vapour generators was passed into the base of a secondary dilution vessel. A further supply of clean and dry air was supplied to Groups 2 and 3. The air supply to Group 4 was provided solely by the vapour generation system.
- Temperature, humidity, pressure in air chamber: The mean temperatures in chambers ranged between 22.6 °C +-1.13 (Group 1 Chamber) and 24.3 22.6 °C +- 0.99 (Group 4 Chamber). The mean relative humidity (RH) in chambers ranged between 30% +- 6.2 (Group 4 Chamber) and 42% +- 6.6 (Group 1 Chamber) .
- Air flow rate: about 150 l/minute initially and about 100 l/minute from exposure 40 onward to give the final chamber conconcentrations.
- Air change rate: not reported
- Method of particle size determination: not relevant
- Treatment of exhaust air: not reported
TEST ATMOSPHERE
- Brief description of analytical method used: Gas Chromatograph was used to measure the concentration of H GALDEN in the test atmospheres within the four inhalation chambers.
- Samples taken from breathing zone: yes. Chamber atmosphere was sampled in sequence from each of the four exposure chambers and from one point within each chamber. Air from each chamber was continually drawn through a transfer line, which was therefore equilibrated with the mean concentration from each chamber. Every seven minutes, air from the transfer lines was swiched to the injection loop pf the gas chromatograph for automated analysis and data logging. When not being sampled, these transfer lines were pumped to waste.
VEHICLE (if applicable)
- Justification for use and choice of vehicle: air
- Composition of vehicle: air
- Type and concentration of dispersant aid (if powder): not relevant
- Concentration of test material in vehicle: 1014, 3297, 10075 ppm
- Lot/batch no. of vehicle (if required): not relevant
- Purity of vehicle: not relevant - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The samples of chamber atmosphere were injected into a gas chromatograph, which was calibrated using vapour standards prepared in gas sampling bags.
Vapour samples are collected using an automated system fitted with electrically controlled valves, which are manipulated using Chamber Environment Monitoring System (CEMS-2) software.
The test atmosphere is drawn directly from the inhalation chamber through the sample line to the gas-sampling valve located on the GC. Initially, the gas-sampliong valve of the GC is set to the "load" position after 60 seconds. Simultaneously, the GC activates the start of the run sequence.
Chromatographic conditions:
Analytical column: DB.1, 5 micrometer film thickness, 30 m x 0.53 mm i.d.
Carrier gas: Helium (2.1 ml/minute)
Split ratio 1:25
Oxidant: Air ( 330 ml/minute)
Fuel: Hydrogen (33 ml/minute)
Injection volume: 500 microliter via an automated gas valve
Injection temperature: 200 °C
Detector temperature: 200 °C
Range: 1000
Gas sample valve: Off at 2.5 minute
Retention time H GALDEN: approximately 0.6-2.3 minutes (analysis for major peak at 0.9 minutes)
- Duration of treatment / exposure:
- 6 hours/day
- Frequency of treatment:
- 5 days/week for 13 consecutive weeks.
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0 ppm (analytical)
- Dose / conc.:
- 1 014 ppm (analytical)
- Remarks:
- Target: 1000 ppm
- Dose / conc.:
- 3 297 ppm (analytical)
- Remarks:
- Target: 3300 ppm
- Dose / conc.:
- 10 075 ppm (analytical)
- Remarks:
- Target: 10000 ppm
- No. of animals per sex per dose:
- 20 (10 males + 10 females)
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: the dose levels (1000, 3300, 10000 ppm) were selected in consultation with the sponsor, on the results obtained in a 14-day preliminary toxicity study performed in the same laboratory.
- Rationale for animal assignment (if not random): random - Positive control:
- no
Examinations
- Observations and examinations performed and frequency:
- CLINICAL OBSERVATIONS: Yes
Dated and signed records of appearence, change and disappearence of clinical signs were maintened in clinical history sheets for individual animals.
Sign of ill health, together with any behavioural change or response to tratment, were recorded.
In addition detailed observations were made according to the following time schedule:
-Daily during exposure period as following:
1. Pre-exposure observation, 2. During exposure, 3. As each animal is returned to its home cage, 4. As late as possible in the working day.
Throughout the study, checks were made early in the working day and again in the afternoon to look for dead or moribund animals.
DETAILED PHYSICAL EXAMINATION AND ARENA OBSERVATION
Once prior to the study start, in each week of exposures, a detailed physical examination was performed on all animals. The observations took place, at the weekend, when there were no exposures, at approximately the same time of day on each occasion. After removal from the cage, the animal was assessed for physical condition and behaviour during handling and after being placed in a standard arena. Particular attention was made to possible signs of neurotoxicity, such as convulsions, tremor and abnormal gait or behaviour, as well as to any audible respiratory noise. Any deviations from normal were recorded.
BODY WEIGHT: Yes
- Time schedule for examinations: one week before the start of exposure, on the day that treatment commenced, each week thereafter and also prior to necropsy.
FOOD CONSUMPTION: Yes
The quantity of food consumed by each cage of rats was recorded on a weekly basis, commencing 1 week before the start of exposures.
Food intake per rat (g/rat/week) was calculated using the total amount of food given to and left by each cage in each group and the number of rats in each cage.
FOOD EFFICIENCY: No
WATER CONSUMPTION: Yes
The quantity of water consumed by each cage of rats was recorded on a daily basis, commencing 1 week before the start of exposures.
Water intake per rat (g/rat/day) was calculated using the total amount of water given to and left by each cage in each group and the number of rats in each cage.
OPHTHALMOSCOPIC EXAMINATION: Yes
The eyes of all rats were examined once before the start of dosing.
All control and high dose group rats were examined during Week 13 of dosing (prior to dosing on the day).
The following ocular structures were examined: adnexa, conjunctiva, cornea, sclera, anterior chamber, iris (pupil dilated), lens, vitreous and ocular fundus.
HAEMATOLOGY: Yes
- Time schedule for collection of blood: on Week 13 of exposure from all rats.
- Animals fasted: Yes, overnight
- How many animals: 80
- The following parameters were examined: Haematocrit, Haemoglobin, Erythrocyte count, Mean cell haemoglobin concentration , Mean cell volume, Mean cell haemoglobin, Total leucocyte count (Neutrophilis, Lymphocytes, Eosinophils, Basophils, Monocytes, Large unstained cells), Plateled count, Reticulocyte count, Cell morphology, Prothrombin time, Activated partial thromboplastin time.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: on Week 13 of exposure from all rats.
- Animals fasted: Yes, overnight
- How many animals: 80
- The following parameters were examined: Glucose, Total protein, Albumin/Globulin (A/G) ratio, Urea, Creatinine, Alkaline phosphatase, Alanine amino-transferase, Aspartate amino-transferase, Gamma Glutamyl transpeptidase, Creatine phosphokinase, Total bilirubin, Sodium, Potassium, Calcium, Inorganic phosphorus, Chloride, Cholesterol, Triglycerides.
URINALYSIS: Yes
- Time schedule for collection of urine: on Week 13 of exposure from all rats
- Metabolism cages used for collection of urine: Yes. Rats were placed overnight in individual urine cages.
- Animals fasted: Food and water were withheld overnight
- The following parameters were examined: Appearance, Volume, pH, Specific gravity, Protein, Sodium, Potassium, Chloride, Total reducing substances, Glucose, Ketones, Bilirubin, Blood pigments.
For microscopic examination, a portion of the urine sample was centrifuged and the resulting deposit was examined for the presence of the following: Epithelial cells, Leucocytes, Erythrocytes, Crystals, Renal tubule casts, Spermatozoa and precursors, Other abnormal constituents
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: During Week 12; prior to the start of exposure; during the weekend, when no exposures were in progress.
- Dose groups that were examined: All animals
- Battery of functions tested: sensory activity, grip strength, motor activity
Sensory reactivity: Approach response, touch response, auditory startle response, tail pinch response.
Grip strength: forelimb and hindlimb grip strength was measured. Two trials were performed.
Motor activity: motor activity was recorded using an infra-red detector. The following categories were recorded: time spent in locomotory activity, non-locomotor activity, in no movement. The number of occurrences (events) of each category is also recorded. The test session for each animal was one hour, with data being collected every 2 minutes. - Sacrifice and pathology:
- Following 13 weeks of exposure the rats were sacrificed. The examinations took place over 2 days, and, for animals sacrifieced on the second day, exposure were performed on Day 1 of Week 14.
GROSS PATHOLOGY: Yes
All rats were subjected to a detailed macroscopic examination.
The following organs from all animals were dissected free of fat and weighed: adrenals, kidney, ovaries, thymus, brain, liver, spleen, uterus with cervix, epididymides, lungs including bronchi, testes, heart.
HISTOPATHOLOGY: Yes
The following tissues were examined: abnormalities*, adrenals, aorta (thoracic), brain, caecum, colon, duodenum, epididymides, eyes, femur (longitudinal section through joint), heart, ileum jejunum, kidneys, larynx (2 levels), liver (section from 2 lobes)*, lungs (section from 4 major lobes including bronchi)*, lymph nodes (mandibular, mesenteric and tracheobronchial), nasal turbinates, oesophagus, ovaries, pancreas, pituitary, rectum, salivary grands, sciatic nerves, seminal vesicles, skeletal muscle (thigh), spinal cord, spleen, sternum, stomach, testes (PAS staining), thymus, thyroid with parathyroids, trachea (including bifurcation), urinary bladder, uterus with cervix.
Groups 1 and 4: all above listed tissues.
Groups 2 and 3: only star(*)marked tissues and, due to treatment-related changes, liver - Other examinations:
- BONE MARROW EXAMINATION
Prior the post mortem examination, a tibial/femoral bone marrow sample was obtained from each animal. Each smear was air-dried and held pending a possible future requirements for examination (a visual assessment for cellularity, distribution and morphology). - Statistics:
- All statistical analysis were performed separately for males and females.
Data relating to food and water consumption were analyzed fon a cage basis. For all other parameters the analysis were performed using the individual animal as experimental unit. Bodyweight data were analysed using weight gains.
A sequence of statistical analysis was used for bodyweight, food and water consumption, clinical pathology, organ weight and grip strength data. Details on the sequence of statistical analysis are reported in the section "Any other information on materials and method".
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- There were no treatment-related effects during the 13 weeks of the treatment period. No observations were observed during or immediately post exposure in any group.
- Mortality:
- no mortality observed
- Description (incidence):
- There were no unscheduled deaths during the study.
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- There were considered to be no effects of treatment on the variable pattern of bodyweight change between the groups.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Description (incidence and severity):
- There were considered to be no effect of treatment on water consumption of males during the 13 weeks of treatment.
Group mean water intake of Group 4 (High dose) females was slightly greater that the concurrent controls over the 13 weeks of exposure, although the differences did not attain statistical significance. There were no dosage related effects on water consumption amongst Low and Intermediate dose females. - Ophthalmological findings:
- no effects observed
- Description (incidence and severity):
- There were no treatment-related findings observed amongst High dose animals during the ophthalmic examinations in Week 13.
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- There were considered to be no treatment-related findings in the haematological parameters investigated in Week 13.
Occasional values were statistically different from Controls (i.e. mean cell haemoglobin concentration (MCHC) levels of High dose female and prothrombin time (PT) and activated partial thromboplastin time (APTT) of treated females). In the absence of dosage-responses and correlation amongst sexes, these findings are considered not to be of toxicological significance. - Clinical biochemistry findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Group mean creatine phosphokinase (CPK) levels were lower in all treated groups (statistically significantly lower for all treated females) compared with the control in Week 13. However, the Control values for males and females were remarkably high (expected values are in the region of 150 U/L) and as such these changes are of no toxicological importance.
Group mean urea levels were slightly lower than Control amongst High dose animals, with statistical significance being attained for males. In the absence of a dose response this change is considered to be of no toxicological significance.
Group mean total protein levels (due to higher albumin levels) for Intermediate and High dose males and females were slightly higher than the Controls with the values for females attaining statistical significance. In the absence of a dose response this change is considered to be of no toxicological significance.
Although other slight inter-group differences in the biochemical parameters investigated in Week 13 occasionally attained statistical significance, these findings were considered incidental and of no toxicological significance. - Urinalysis findings:
- no effects observed
- Description (incidence and severity):
- Group mean urinary volume was lower in High dose males when compared with the Controls with a consequent lower pH and higher specific gravity. However, in the absence of similar findings amongst females, and no effects on water consumption, these changes are no of toxicological significance.
There were considered to be non effects of treatment on the remaining urinalysis parameters investigated. - Behaviour (functional findings):
- effects observed, non-treatment-related
- Description (incidence and severity):
- SENSORY REACTIVITY and GRIP STRENGTH: In week 12 group mean forelimb grip strength of Intermediate dose and High dose female rats was slightly but statistically significantly lower than the Controls. In the absence of effects in males, no dosage-relationship and no similar effect on hindlimb grip strength, this change is considered to be of no toxicological significance.
There were considered to be no effects of treatment on group mean hindlimb grip strength.
Sensory reactivity was considered unaffected by treatment in Week 12.
MOTOR ACTIVITY: There were considered to be no treatment-related effects in the time spent in locomotory activity in Week 12. - Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- Following 13 weeks of treatment, group mean body weight-adjusted kidney weight were statistically significantly higher than Controls, for Intermediate dose females and High dose males and females. However, in the absence of any pathological changes, this change is considered to be of no toxicological significance.
Group mean body weight-adjusted liver weights were statistically significantly higher in High dose animals following 13 weeks of treatment.
Group mean thymus weights ( bodyweight-adjusted fro females) were higher in High dose animals, with statistically significance being attained for female. However, since no dosage related trend was apparent the change is considered to be of no toxicological significance.
There were considered to be no further effects on the organ weight investigated. - Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- The macroscopic examinations performed at termination revealed no changes attributable to treatment with HFPE.
The incidence and distribution of all findings were considered to fall within the expected background range of macroscopic changes. - Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Findings considered to be related with treatment were reported in the liver:
Centrilobular hepatocyte hypertrophy was reported in all Group 4 males, the majority of Group 4 female and a proportion of Group 3 males and females, but no in Group 2 or Control animals.
All other findings were considered to be incidental and of no toxicological significance. - Histopathological findings: neoplastic:
- no effects observed
Effect levels
open allclose all
- Key result
- Dose descriptor:
- NOEC
- Effect level:
- 1 014 ppm (analytical)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- histopathology: non-neoplastic
- Key result
- Dose descriptor:
- NOAEC
- Effect level:
- 10 075 ppm (analytical)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- histopathology: non-neoplastic
Target system / organ toxicity
- Key result
- Critical effects observed:
- no
Any other information on results incl. tables
RESULTS of MICROSCOPIC EXAMINATION
Treatment related findings
MALES | FEMALES | ||||||||
Group / (Concentration) | 1 Control group |
2 (1014 ppm) |
3 (3297 ppm) |
4 (10075 ppm) |
1 Control group |
2 (1014 ppm) |
3 (3297 ppm) |
4 (10075 ppm) |
|
Centrilobular hepatocyte hypertrophy | Total | 0 | 0 | 5a | 10c | 0 | 0 | 3 | 9c |
Minimal | 0 | 0 | 5 | 3 | 0 | 0 | 3 | 6 | |
Slight | 0 | 0 | 0 | 7 | 0 | 0 | 0 | 3 | |
Number of livers examined | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | |
Statistical significance compared to Control Group 1:a: p < 0,05 ; c : p < 0.001 |
Applicant's summary and conclusion
- Conclusions:
- The only biologically significant change seen in this study on H GALDEN was centrilobular hypertrophy of the liver in the majority of High dose animals (correlating with an increased bodyweight-adjusted liver weight) and a proportion of Intermediate animals. There was no concurrent alteration of biochemical parameters (e.g., hepatic enzymes). As this is considered to be an adaptive response to exposure of the test material rather than an indication of toxicity it is concluded that No Adverse Effect Concentration (NOAEC) was 10075 ppm (115209 mg/m3) and that the No Effect Concentration (NOEC) was 1014 ppm (11595 mg/m3).
- Executive summary:
H GALDEN was administered to rats by whole body inhalation exposure for 13 weeks. Three groups (each of 10 males and 10 females) were exposed to target concentrations of 1000, 3300 and 10000 ppm, 6 hours a day, 5 days a week for 13 consecutive weeks. A fourth group acting as a control was exposed to air alone.
During the study clinical signs, physical examination, arena observations were recorded. Bodyweight and food consumption were recorded weekly. Water consumption was recorded daily. Sensory reactivity, grip strength and motor activity were recorded for all animals in Week 12. Opthalmoscopy was performed on all animals pre-dose and in Week 13. In Week 13, haematology, biochemistry and urinalysis was undertaken. Following the 13-week period, all animals were sacrificed on the day following the last exposure
and subjected to a full macroscopic examination and a range of organ weights recorded. Histopathological examinations were carried out on selected tissues from all animals (dependent upon dose group).
Mean analysed vapour concentrations of HFPE were 1014, 3297 and 10075 ppm. These levels were in good agreement with the target exposure levels of 1000, 3300 and 10000 ppm.
The only biologically significant change seen in this study was centrilobular hypertrophy of the liver in the majority of high dose animals (correlating with an increased in bodyweight-adjusted liver weight) and a proportion of intermediate dose animals. As this is considered to be an adaptive response to exposure of the test material rather than an indication of toxicity it is concluded that the No Adverse Effect Concentration (NOAEC) was 10075 ppm (115209 mg/m3) and that the No Effect Concentration (NOEC) was 1014 ppm (11595 mg/m3).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.